2003
DOI: 10.1002/jmv.10464
|View full text |Cite
|
Sign up to set email alerts
|

Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy

Abstract: We examined whether lamivudine treatment, in addition to the rapid decline of HBV serum DNA described in a large number of laboratories, causes changes in composition and amount of discernable circulating viral DNA and RNA. Nucleic acids were extracted from serial serum samples of a patient infected chronically and treated with lamivudine for 14 weeks. Three sequence segments of the HBV genome synthesized successively during replication, X, C, and X-preC, were analyzed by competitive PCR and RT/PCR. In additio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

2
37
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 25 publications
(39 citation statements)
references
References 19 publications
2
37
0
Order By: Relevance
“…The presence of HBV RNA in serum samples of patients with HBV infection has been previously reported. [19][20][21] Because the TMA-HPA uses RNA transcription and amplification of transcripts by T7 RNA polymerase, 22 we assumed that the discrepancy was a result of the presence of HBV RNA in the serum of LAM-and ETV-treated patients. The presence of HBV RNA in a patient treated with LAM was reported previously.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…The presence of HBV RNA in serum samples of patients with HBV infection has been previously reported. [19][20][21] Because the TMA-HPA uses RNA transcription and amplification of transcripts by T7 RNA polymerase, 22 we assumed that the discrepancy was a result of the presence of HBV RNA in the serum of LAM-and ETV-treated patients. The presence of HBV RNA in a patient treated with LAM was reported previously.…”
Section: Discussionmentioning
confidence: 99%
“…The presence of HBV RNA in a patient treated with LAM was reported previously. 21 In that report, the authors mainly analyzed truncated HBV RNA, which they assumed was transcribed from the integrated genome. 20,21 They showed a large difference between HBV DNA and truncated HBV RNA, which did not decrease during LAM therapy.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The predominant antiviral strategy against HBV is to attack the reverse transcriptase. Unsurprisingly, HBV reverse transcriptase inhibitors lead to drug-resistant mutants in HBV (7,24,30) and also human immunodeficiency virus (14). Resistance can have broader consequences because of the extensive gene overlap in HBV, since some reverse transcriptase mutations lead to surface protein that is insensitive to antibodies generated by the HBV vaccine (25).…”
mentioning
confidence: 99%